{
  "id": "breast-cancer-cdk46-by-regimen",
  "display_name": "ER+/HER2- MBC (By Regimen)",
  "cohort": "ER+/HER2- Metastatic Breast Cancer, All Patients, by Regimen, Q1 2023",
  "insight_type": "Treatment Patterns by Regimen",
  "summary": "Abemaciclib is the most commonly used CDK4/6 inhibitor (52%) followed by palbociclib (28%) and ribociclib (20%). All are guideline-appropriate options.",
  "recommendation": "Continue current CDK4/6 inhibitor selection patterns while monitoring for any emerging efficacy or cost differences between agents.",
  "financial_impact": {
    "annual_opportunity": "$0/year",
    "math": "Current regimen selection practices are appropriate based on the available clinical and economic data."
  },
  "financial_impact_description": "Current regimen selection practices are appropriate based on the available clinical and economic data.",
  "peer_financial_impact": 50000,
  "peer_financial_impact_description": "Minor opportunity of $50,000 annually through optimized agent selection compared to peers.",
  "action_steps": [
    {
      "text": "Continue to monitor comparative efficacy data between CDK4/6 inhibitors",
      "icon": "chart-bar"
    },
    {
      "text": "Evaluate the clinical and financial impact of current agent selection",
      "icon": "user-group"
    }
  ],
  "peer_action_steps": [
    "Review agent selection criteria and compare to best-performing organizations",
    "Consider potential value-based contracts for preferred agents"
  ],
  "chart_data": {
    "categories": [
      "Abemaciclib",
      "Palbociclib",
      "Ribociclib",
      "Everolimus",
      "Other"
    ],
    "values": [
      52,
      28,
      20,
      0,
      0
    ],
    "peer_values": [
      45,
      30,
      25,
      0,
      0
    ],
    "target_values": [
      50,
      30,
      20,
      0,
      0
    ]
  },
  "drilldowns": [],
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      {
        "name": "Abemaciclib",
        "value": 52,
        "gap": 0,
        "highlight": true
      },
      {
        "name": "Palbociclib",
        "value": 28,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Ribociclib",
        "value": 20,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Everolimus",
        "value": 0,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Other",
        "value": 0,
        "gap": 0,
        "highlight": false
      }
    ],
    "benchmark": 65,
    "nccn_target": 65
  },
  "clinical_impact": {
    "description": "Clinical impact analysis based on outcomes data and peer-reviewed literature.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+3.2 months",
        "description": "Potential median progression-free survival improvement"
      },
      {
        "type": "OS",
        "value": "+5.1 months",
        "description": "Potential median overall survival improvement"
      },
      {
        "type": "QoL",
        "value": "+15%",
        "description": "Enhanced quality of life measures"
      }
    ],
    "quantitative": "+5.1 months OS"
  },
  "weighted_score": 94
}